Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$27,073 Mln
P/E Ratio
--
P/B Ratio
44.53
Industry P/E
--
Debt to Equity
0.02
ROE
-0.95 %
ROCE
-76.35 %
Div. Yield
0 %
Book Value
0.54
EPS
-0.31
CFO
$-341.32 Mln
EBITDA
$-348.02 Mln
Net Profit
$-891.55 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| 35.11 | 17.04 | 2.51 | 524.61 | 139.05 | 46.20 | 8.94 |
|
BSE Sensex*
| 2.62 | 3.73 | 5.80 | 8.91 | 11.76 | 20.12 | 11.35 |
|
S&P Midcap 400
| -8.80 | -4.26 | -12.25 | -1.81 | 4.06 | 11.99 | 6.45 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Summit Therapeutics - ADR
| 573.09 | -38.59 | 57.99 | -42.77 | 193.75 | 39.13 | -89.49 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 254.85 | 32,558.66 | -- | 362.29 | |
| 131.87 | 14,047.06 | -- | -8.58 | |
| 150.13 | 26,567.10 | 20.09 | 22.55 | |
| 297.04 | 13,312.86 | 11.82 | 19.23 |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific... antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131 Read more
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
Co-CEO & Executive Chairman
Mr. Robert W. Duggan
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Summit Therapeutics Inc - ADR stood at $ 436 Mln as on 31-Dec-24
The share price of Summit Therapeutics Inc - ADR is $24.11 (NASDAQ) as of 28-Apr-2025 16:26 EDT. Summit Therapeutics Inc - ADR has given a return of 139.05% in the last 3 years.
Summit Therapeutics Inc - ADR has a market capitalisation of $ 27,073 Mln as on 28-Apr-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Summit Therapeutics Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Summit Therapeutics Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Summit Therapeutics Inc - ADR.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131
The CEO & director of Mr. Robert W. Duggan. is Summit Therapeutics Inc - ADR, and CFO & Sr. VP is Mr. Robert W. Duggan.
There is no promoter pledging in Summit Therapeutics Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,132
|
|
|
2,593
|
|
|
1,405
|
|
|
1,318
|
| Summit Therapeutics Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-94.9
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Summit Therapeutics Inc - ADR was $-221 Mln.
$0.65
(
